Latest News

Dr. Reddy’s Laboratories launches Tadalafil Tablets USP in the U.S. Market




HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA). The Adcirca brand and generic had U.S. sales of approximately $490 million MAT for the most rec

Source link

Related posts

Potential seen for tailoring treatment for acute myeloid leukemia

Newsemia

Schick Creates Video Game About Shaving Heads Amid Lockdown

Newsemia

Sleep disturbances linked to mental health problems among survivors of natural disaster

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy